CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: July 26, 2005
Result type: Reports
Project Number: SR0038-000
Product Line: Reimbursement Review

Generic Name: Abacavir/lamivudine

Brand Name: Kivexa

Manufacturer: GlaxoSmithKline

Therapeutic Area: HIV infection

Indications: HIV infection

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: December 7, 2005

Recommendation Type: List in a similar manner to other drugs in class